Pemetrexed + Carboplatin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non Small Cell Lung Carcinoma
Conditions
Non Small Cell Lung Carcinoma
Trial Timeline
Apr 1, 2008 → Dec 1, 2012
NCT ID
NCT01836575About Pemetrexed + Carboplatin
Pemetrexed + Carboplatin is a phase 3 stage product being developed by Eli Lilly for Non Small Cell Lung Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01836575. Target conditions include Non Small Cell Lung Carcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01020786 | Approved | Completed |
| NCT00906282 | Phase 2 | Completed |
| NCT01836575 | Phase 3 | Completed |
| NCT00494026 | Phase 2 | Terminated |
| NCT00383266 | Phase 2 | Terminated |
| NCT00350792 | Phase 2 | Completed |
| NCT00072865 | Phase 2 | Completed |
Competing Products
20 competing products in Non Small Cell Lung Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 30 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 52 |
| Selpercatinib | Eli Lilly | Pre-clinical | 23 |
| Pemetrexed + Cisplatin + Placebo + Pemetrexed | Eli Lilly | Phase 3 | 77 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 36 |
| Pemetrexed | Eli Lilly | Pre-clinical | 23 |
| pemetrexed + erlotinib | Eli Lilly | Phase 2 | 52 |
| LY3295668 Erbumine | Eli Lilly | Phase 1 | 33 |
| FYB206 + FYB206 + Keytruda | Formycon AG | Phase 3 | 69 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab | MAIA Biotechnology | Phase 2 | 44 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone | MAIA Biotechnology | Phase 3 | 69 |
| pemetrexed + cisplatin | Eli Lilly | Phase 2 | 52 |
| gemcitabine + carboplatin + cisplatin | Eli Lilly | Phase 2 | 52 |
| Cetuximab | Eli Lilly | Phase 1 | 33 |
| pemetrexed + docetaxel | Eli Lilly | Phase 3 | 77 |
| enzastaurin + pemetrexed + docetaxel + carboplatin | Eli Lilly | Phase 2 | 52 |
| PemCarbo + Pem only | Eli Lilly | Phase 3 | 77 |
| TNG456 + abemaciclib | Eli Lilly | Phase 1/2 | 41 |
| pemetrexed + cisplatin | Eli Lilly | Phase 1/2 | 41 |
| LY2875358 + Erlotinib | Eli Lilly | Phase 2 | 52 |